STAT Plus: Pharmalittle: Prices for active ingredients rise in China due to coronavirus; Grassley presses his drug pricing bill
Top of the morning, and a fine one it is. Warm and sunny skies are enveloping the Pharmalot campus, where the short person is sleeping in thanks to a week-long break from the usual schoolhouse routine and we are busy brewing cups of stimulation. Feel free to join us. The neurons need a little help now and then, wouldn’t you agree? Meanwhile, we have assembled a few items of interest to help you along. Hope you have a productive day and please keep in touch. We appreciate the suggestions and tips.
A Senate bill to control prescription drug costs seemed to have everything it needed: bipartisan backing, President Trump’s endorsement, and broad public support. But its status on legislative life support reveals the perils of tackling one of the nation’s most hot-button topics months before a presidential election, The Washington Post notes. Even though Trump has said he supports the measure, he has stopped far short of trying to ensure its passage. Meanwhile, the top Senate Republican and Democrat have yet to embrace the legislation, though for opposite reasons.
Continue to STAT Plus to read the full story…
